uridine monophosphate has been researched along with Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted in 157 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (0.64) | 29.6817 |
| 2010's | 147 (93.63) | 24.3611 |
| 2020's | 9 (5.73) | 2.80 |
| Authors | Studies |
|---|---|
| Bao, H; Furman, PA; McBrayer, TR; Micolochick Steuer, HM; Murakami, E; Obikhod, A; Otto, MJ; Ramesh, M; Schinazi, RF; Stuyver, LJ; Whitaker, T | 1 |
| Abd-Aal, MS; Abdel-Hafez, AS; Abdel-Hamid, TM; Abdel-Rahman, RZ; Abdelsalam, MFA; Elaatar, MB; Elgohary, MA; Elkady, AO; Elnagar, MT; Elnagdy, TR; Elsaied, MA; Emam, ME; Fatoh, AR; Hamada, MM; Hasan, EM; Helmy, S; Ibrahim, AA; Lotfy, HH; Mubark, MA; Nawar, OM; Sakr, MA; Seadawy, MG; Selem, MA; Shehata, MM; Zaki, AI | 1 |
| Awad, J; Balsara, K; Brinkley, DM; Brown Sacks, S; Danter, M; Darragh, C; Fowler, R; Lindenfeld, J; Menachem, J; O'Dell, H; Ooi, H; Perri, R; Punnoose, L; Ruzevich-Scholl, S; Schlendorf, K; Shah, A; Smith, S; Wigger, M; Zalawadiya, SK | 1 |
| Alonso López, S; Guerra Romero, AR; Pérez Figueras, M | 1 |
| Farcomeni, A; Gioia, S; Nardelli, S; Ridola, L; Riggio, O; Rosati, D | 1 |
| Lazarus, JV; Lens, S | 1 |
| Althoff, KN; Elion, RA; Eron, JJ; Gillman, J; Huhn, GD; Jayaweera, DT; Mills, A; Mounzer, K; Moyle, G; Patel, SV; Radtchenko, J; Santiago, S; Sax, PE | 1 |
| Banga, J; Nagarakanti, S; Nizami, S; Portilla, M; Slim, J; Swaminathan, S | 1 |
| Agarwal, K; Bestwick, J; Drysdale, K; Elsharkawy, AM; Forton, D; Foster, GR; Gelson, W; Mahomed, F; Mutimer, D; Ntuli, Y; Townley, C | 1 |
| Barclay, ST; de Bruin, M; Dillon, JF; Donnan, PT; Fraser, A; Hapca, A; Inglis, SK; Radley, A | 1 |
| Bonacini, M; Brainard, DM; De-Oertel, S; Flamm, SL; Gane, EJ; Gordon, SC; Huang, J; Hyland, RH; Kirby, BJ; Landis, CS; Lawitz, E; Maliakkal, BJ; Ortiz-Lasanta, G; Osinusi, AO; Robson, R; Zhang, J | 1 |
| Abbassi, MM; Ebeid, FS; El-Baraky, IA; El-Sayed, MH; Hassany, M; Sabry, NA | 1 |
| Bhagani, S; Boesecke, C; Brainard, DM; Dvory-Sobol, H; Hyland, RH; Ingiliz, P; Lutz, T; Nelson, M; Rockstroh, JK; Yun, C; Zheng, W | 1 |
| Heil, EL; Hoke, KS; Mattingly Ii, TJ | 1 |
| Sise, ME | 1 |
| Goda, Y; Hakamatsuka, T; Hosoe, J; Kamakura, H; Maruyama, T; Masada, S; Tokumoto, H; Tsujimoto, T; Uchiyama, N | 1 |
| Aschenbrenner, DS | 1 |
| Abaalkhail, F; Ajlan, A; Al Sebayel, M; Al-Hamoudi, W; Al-Jedai, A; Alabbad, S; Broering, D; Elbeshbeshy, H; Elsiesy, H; Saab, S; Shawkat, M; Ullah, W; Yousif, S | 1 |
| Baz, M; Harris, DD; Shafii, AE | 1 |
| Fulco, PP; Lavoie, SR; Sterling, RK | 1 |
| Ikeda, A; Ikeda, K; Inagaki, N; Kokuryu, H; Marusawa, H; Seno, H; Takahashi, K; Takai, A; Ueda, Y | 1 |
| Brainard, DM; Camus, G; Chang, TT; Chen, CY; Chen, JJ; Chen, PJ; Chien, RN; Chu, CJ; Chuang, WL; Hsu, YC; Hu, TH; Jiang, D; Knox, SJ; Liu, CJ; Lo, GH; Massetto, B; McHutchison, JG; Osinusi, A; Peng, CY; Sheen, IS; Tseng, KC; Wang, HY; Yang, JC; Yun, C | 1 |
| Crutcher, EL; Greene, EM; Lenz, DU | 1 |
| Agarwal, K; Carey, I; Lampejo, T | 1 |
| Asensi-Diez, R; Del Rio-Valencia, JC; Madera-Pajin, R; Muñoz-Castillo, I; Yunquera-Romero, L | 1 |
| Scott, LJ | 1 |
| Fung, P; Lingiah, VA; Punnoose, M; Pyrsopoulos, N; Trilianos, P | 1 |
| Bergmann, OM; Björnsson, ES; Fridriksdottir, RH; Gottfredsson, M; Gudnason, T; Hansdottir, I; Heimisdottir, M; Hellard, M; Johannsson, B; Löve, A; Löve, TJ; Olafsson, S; Runarsdottir, V; Sigurdardottir, B; Tyrfingsson, T | 1 |
| Reinke, T | 1 |
| Anderson, PL; Brainard, DM; Bushman, LR; Castillo-Mancilla, JR; Chung, RT; Fierer, DS; Hughes, MD; Kim, AY; Kiser, JJ; MacBrayne, CE; Marks, KM; Naggie, S; Peters, MG; Seifert, SM | 1 |
| Boldt, M; Hassan, MA; Huepfel, W; Lake, JR; Shaukat, AP; Tierney, AR; Wang, Q | 1 |
| Abd Alla, MDA; Al-Azhari, SS; Dawood, RM; El Awady, MK; Elhawary, MA; Galal, AGM | 1 |
| Chu, TC; Fasanmi, EO; MacDonald, BR; Moore, JD; Ojha, RP; Stewart, RA | 1 |
| Abd Elaziz, D; Aiuti, A; Appleby, J; Barzaghi, F; Bernardo, ME; Boeri, E; Calbi, V; Calzatini, F; Canarutto, D; Casiraghi, M; Cestone, E; Cicalese, MP; Ciceri, F; Consiglieri, G; Darin, S; Dionisio, F; Ferrua, F; Finazzi, R; Gabaldo, M; Lucano, C; Marktel, S; Mieli-Vergani, G; Migliavacca, M; Recupero, S; Tucci, F | 1 |
| Boeker, KHW; Buggisch, P; Günther, R; Hüppe, D; Maasoumy, B; Manns, MP; Mauss, S; Müller, T; Sarrazin, C; Vermehren, J; Wedemeyer, H; Zimmermann, T | 1 |
| Herrera, JL; Marshall, MC | 1 |
| Aqel, B; Keaveny, AP; Leise, M; Pungpapong, S; Vargas, HE; Watt, KD; Zhang, N | 1 |
| Chua, JV; Claeys, K; Heil, EL; Hynicka, LM; Vega, AD | 1 |
| Aziz, A; Durazo, F; Hanna, RM; Latt, N; Mikhail, MM; Mitry, A; Saab, S; Sahota, A; Yanny, B | 1 |
| Dupuy, CA; Glotz, D; Parlati, L; Pol, S; Sirmai, L | 1 |
| Morrison, C | 1 |
| Alcazer, V; Charre, C; Cotte, L; Miailhes, P; Ramière, C | 1 |
| Behar, E; Coffin, PO; Fox, R; Hern, J; Kinnard, EN; Matheson, T; Page, K; Santos, GM; Silvis, J; Vittinghoff, E; Walker, J | 1 |
| Brainard, DM; Chung, RT; Fierer, DS; Hughes, MD; Kim, AY; Kiser, JJ; Luetkemeyer, A; Marks, KM; McHutchison, JG; Naggie, S; Peters, MG; Roa, J; Rwema, S; Vu, V | 1 |
| Abdullatif, HM; El Rasheed Abd El Zaher, BA; El Raziky, MS; El-Karaksy, HM; Ghobrial, CM; Mogahed, EA; Ramzi, R | 1 |
| Aizaki, H; Hatanaka, T; Hmwe, SS; Hoshino, T; Kakizaki, S; Naganuma, A; Sato, K; Tateyama, Y; Uraoka, T; Wakita, T; Yoshinari, F | 1 |
| Mole, B | 1 |
| Dalzell, MD | 1 |
| Tse, MT | 1 |
| Borgia, F; Borgia, G; Buonomo, AR; Castaldo, G; Gentile, I | 1 |
| Barrett, L; Bon, D; Chavez, J; Dewar, R; Fauci, AS; Fishbein, D; Gu, W; Herrmann, E; Heytens, L; Highbarger, H; Kleiner, D; Kohli, A; Kotb, C; Kottilil, S; Kwan, R; Lee, YJ; Masur, H; McHutchison, J; Meissner, EG; Nelson, A; Osinusi, A; Polis, MA; Proschan, M; Shivakumar, B; Silk, R; Sneller, M; Subramanian, M; Symonds, WT; Talwani, R; Teferi, G; Wood, BJ; Wroblewski, S; Zhang, X | 1 |
| Berrey, MM; Cornpropst, MT; Denning, J; Gao, B; Lawitz, EJ; Mathias, A; Mo, H; Rodriguez-Torres, M; Symonds, WT | 1 |
| Flisiak, R; Jaroszewicz, J; Parfieniuk-Kowerda, A | 1 |
| Berg, T; Forns, X; Mariño, Z; van Bömmel, F | 1 |
| Ding, X; Gane, EJ; Hyland, RH; McHutchison, JG; Pang, PS; Stedman, CA; Subramanian, GM; Svarovskaia, E; Symonds, WT | 1 |
| Asselah, T | 1 |
| Ferguson, MC | 1 |
| Cohen, J | 2 |
| Corouge, M; Pol, S; Vallet-Pichard, A | 1 |
| Boccaccio, V; Bruno, S | 1 |
| Dieterich, DT; Martel-Laferrière, V | 2 |
| Asselah, T; Marcellin, P | 1 |
| Asselah, T; Halfon, P; Marcellin, P; Schinazi, R | 1 |
| Ford, N; Fortunak, J; Hill, A; Khoo, S; Simmons, B | 1 |
| Sheridan, C | 1 |
| Denning, J; Guedj, J; Lawitz, E; Pang, PS; Perelson, AS; Rodriguez-Torres, M; Symonds, W | 1 |
| Fralick, M | 1 |
| Chung, RT; deLemos, AS | 1 |
| Andronescu, CI; Andronescu, D; Diaconu, S; Purcarea, RM; Tiuca, N | 1 |
| Gane, E; Hunt, SL; Jacobson, IM; Lawitz, E; Nader, F; Nelson, D; Stepanova, M; Younossi, ZM | 1 |
| Watts, G | 1 |
| Callaway, E | 1 |
| Feld, JJ | 1 |
| Chan, J | 1 |
| Adler, H; Lambert, JS | 1 |
| Rice, CM; Saeed, M | 1 |
| Senior, M | 1 |
| Slomski, A | 1 |
| Borgia, G; Buonomo, AR; Gentile, I; Zappulo, E | 1 |
| Henry, L; Lam, B; Younossi, Z | 1 |
| Burki, T | 1 |
| Chung, RT; Feeney, ER | 1 |
| Rolland, S; Vachon, ML | 1 |
| Cooke, G; Hill, A | 1 |
| Carroll, J | 2 |
| Aghemo, A; Colombo, M; Donato, MF; Maggioni, M; Malinverno, F; Monico, S; Reggiani, P | 1 |
| Brainard, D; Chodavarapu, K; Crespo Garcia, J; De Knegt, R; Doehle, B; Drenth, JP; Gontcharova, V; Hedskog, C; McHutchison, JG; Miller, MD; Mo, H; Stamm, LM; Svarovskaia, E | 1 |
| Donaldson, EF; Harrington, PR; Naeger, LK; O'Rear, JJ | 1 |
| Bureau, C; Danjoux, M; Delabaudière, C; Dörr, G; Izopet, J; Kamar, N; Lavayssière, L; Muscari, F; Peron, JM; Rostaing, L; Sallusto, F | 1 |
| Beavers, JW; Klibanov, OM; Summers, BB | 1 |
| Price, JC; Terrault, NA | 1 |
| Abd-Rabou, AA; Belousova, V; Mousa, SA | 1 |
| Wapner, J | 1 |
| Kuehn, BM | 1 |
| Cook, C; Phelan, M | 1 |
| Afdhal, N; Arterburn, S; Befeler, A; Brown, R; Chung, RT; Curry, MP; Denning, J; Everson, G; Fenkel, JM; Forns, X; Gane, E; Gordon, F; Kuo, A; McHutchison, JG; McNair, L; Moonka, D; O'Leary, J; Saab, S; Schiano, T; Schiff, E; Subramanian, GM; Svarovskaia, E; Symonds, WT; Terrault, NA | 1 |
| Foster, GR | 1 |
| Chan, E; Gandhi, M; Lim, SG | 1 |
| Stepanova, M; Younossi, Z | 1 |
| Arterburn, S; Brainard, D; Brown, RS; Charlton, M; Curry, MP; Denning, J; Dvory-Sobol, H; Fontana, RJ; Forns, X; Gane, E; Gilroy, R; Kirby, B; Kwo, PY; Manns, MP; McHutchison, JG; Muir, AJ; Samuel, D; Symonds, WT; Teperman, L; Terrault, NA | 1 |
| Goozner, M | 1 |
| Beaumont, JL; Beckerich, F; Cordonnier, C; Gautier, E; Hézode, C; Maury, S; Robin, C | 1 |
| Agudelo, EZ; Campos-Varela, I; Carlson, L; Straley, S; Terrault, NA | 1 |
| Alqahtani, SA; Dhingra, A; Kapoor, S | 1 |
| Firpi, RJ; Hilgenfeldt, E | 1 |
| Charlton, MR; Gallegos-Orozco, JF | 1 |
| Aghemo, A; Donato, MF | 1 |
| Adhoute, X; Ansaldi, C; Bourlière, M; Castellani, P; Oules, V | 1 |
| Baiguera, C; Panzeri, C; Puoti, M; Rossotti, R | 1 |
| Hablas, A; Hutton, DW; Kim, DD; Raouf, AA; Salama, M; Seifeldin, IA; Soliman, AS | 1 |
| Schwartz, M | 1 |
| Serfaty, L | 1 |
| Bennett, M; Bernstein, D; Cooper, JN; Freilich, BF; Ghalib, R; Gitlin, N; Harlan, W; Hawkins, T; Hennicken, D; Hughes, EA; Kowdley, KV; Lalezari, JP; Lawitz, E; McPhee, F; Nelson, DR; Oguchi, G; Ortiz-Lasanta, G; Pockros, PJ; Rabinovitz, M; Rana, K; Ravendhran, N; Sheikh, AM; Thuluvath, PJ; Varunok, P; Younes, ZH | 1 |
| Denk, G; Eberle, J; Guba, M; Kaspar, M; Kolligs, F; Pichler, M; Seybold, U; Spannagl, M; Stemberger, M | 1 |
| Aqel, B; Chervenak, AE; Henry, TM; Keaveny, AP; Leise, M; Murphy, JL; Pungpapong, S; Ryland, K; Vargas, HE; Watt, KD; Werner, KT | 1 |
| Hayward, P | 1 |
| Manns, MP; Wedemeyer, H; Zeuzem, S | 1 |
| Brault, P; Klotz, C; Mallet, V; Pol, S; Sultanik, P | 1 |
| Agrawal, S; Kwo, PY | 1 |
| Bagcchi, S | 1 |
| Fazel, Y; Golabi, P; Lam, B; Younossi, Z | 1 |
| Kmietowicz, Z | 1 |
| McCarthy, M | 1 |
| Berg, T; Manns, MP; Zeuzem, S | 1 |
| Klibanov, OM; Lomberk, M | 1 |
| Benhaim, S; Borentain, P; Colson, P; Dhiver, C; Gerolami, R; Tamalet, C | 1 |
| Brainard, DM; Chung, RT; Doehle, B; Gustafson, J; Kim, AY; Lauer, GM; Liu, L; McHutchison, JG; Mo, H; Pang, PS; Simon, TG; Stamm, LM | 1 |
| Gibson, W; Klibanov, OM; Mullins, C | 1 |
| Ryder, SD; Thiagarajan, P | 1 |
| Dominguez-Dominguez, L; Jarrin-Estupiñan, ME; Kessler-Saiz, P; Marchan-Lopez, A | 1 |
| Chandrasekar, PH; Surapaneni, M; Wahba, MR | 1 |
| Backus, LI; Belperio, PS; Loomis, TP; Mole, LA; Shahoumian, TA | 1 |
| Beyer, P; de Joncheere, K; Hill, S; Iyengar, S; Tay-Teo, K; Vogler, S; Wiktor, S | 1 |
| Berry, K; Beste, LA; Chang, MF; Green, PK; Ioannou, GN; Lowy, E; Su, F; Tsui, JI | 1 |
| Afdhal, NH; Brainard, DM; Chuang, SM; Ding, X; Doehle, BP; Dvory-Sobol, H; Gane, EJ; Kowdley, KV; Lawitz, E; Ma, J; McHutchison, JG; Miller, MD; Mo, H; Pang, PS; Sarrazin, C; Svarovskaia, ES | 1 |
| Bryce, CL; Chidi, AP; Donohue, JM; Fine, MJ; Landsittel, DP; Myaskovsky, L; Rogal, SS; Smith, KJ; Switzer, GE; Tsung, A | 1 |
| Beckman, AL; Bilinski, A; Boyko, R; Bruce, RD; Camp, GM; Gonsalves, GS; Lim, JK; Wall, AT; Wang, EA | 1 |
| Cuenca-Lopez, F; Rivero, A; Rivero-Juárez, A | 1 |
| Heppt, F; Sticherling, M | 1 |
| Huysentruyt, K; Leclercq, G; Scheers, I; Smets, F; Sokal, EM; Stephenne, X; Varma, S | 1 |
| Chen, YS; Kao, JH; Liu, CH; Wang, SS | 1 |
| Backus, LI; Belperio, PS; Bhattacharya, D; Goetz, MB; Loomis, TP; Mole, LA; Shahoumian, TA | 1 |
| Bergin, C; Cannon, M; Courtney, G; Crosbie, O; De Gascun, CF; Fanning, LJ; Feeney, E; Gray, E; Houlihan, DD; Kelleher, B; Lambert, JS; Lee, J; Mallon, P; McConkey, S; McCormick, A; McKiernan, S; McNally, C; Murray, F; Norris, S; O'Leary, A; Sheehan, G; Stewart, S; Walsh, C | 1 |
| Lawitz, EJ; Membreno, FE | 1 |
| Rachakonda, S; Reddy, PG; Ross, BS; Sofia, MJ; Zhang, HR | 1 |
| Bao, D; Chang, W; Chun, BK; Du, J; Espiritu, CL; Furman, PA; Jiang, Y; Keilman, M; Ross, BS; Sofia, MJ; Steuer, HM; Zhang, HR | 1 |
| Chee, GM; Poordad, F | 1 |
| Pockros, PJ | 1 |
| Desoky, OS; Elfiky, AA; Elshemey, WM; Gawad, WA | 1 |
32 review(s) available for uridine monophosphate and Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted
| Article | Year |
|---|---|
Interferon-free direct-acting antiviral therapy for acute hepatitis C virus infection in HIV-infected individuals: A literature review.
Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C; HIV Infections; Humans; Ribavirin; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Viral Load | 2018 |
Ledipasvir/Sofosbuvir: A Review in Chronic Hepatitis C.
Topics: Antiviral Agents; Benzimidazoles; Coinfection; Drug Combinations; Drug Therapy, Combination; Fluorenes; Genotype; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2018 |
A novel promising therapeutic option against hepatitis C virus: an oral nucleotide NS5B polymerase inhibitor sofosbuvir.
Topics: Administration, Oral; DNA-Directed RNA Polymerases; Enzyme Inhibitors; Hepacivirus; Hepatitis C; Humans; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins | 2013 |
Emerging treatments for hepatitis C.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Discovery; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate | 2013 |
New concepts of sofosbuvir-based treatment regimens in patients with hepatitis C.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C; Humans; Prodrugs; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2014 |
Sofosbuvir for the treatment of hepatitis C virus.
Topics: Antiviral Agents; DNA-Directed RNA Polymerases; Hepacivirus; Hepatitis C; Sofosbuvir; Uridine Monophosphate; Virus Physiological Phenomena | 2014 |
Treatment of hepatitis C virus genotype 3-infection.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Interferon-alpha; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; Sofosbuvir; Standard of Care; Time Factors; Treatment Outcome; Uridine Monophosphate; Valine; Viral Nonstructural Proteins; Viral Proteins | 2014 |
Management of HCV patients with cirrhosis with direct acting antivirals.
Topics: Algorithms; Aminoisobutyric Acids; Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Leucine; Liver Cirrhosis; Oligopeptides; Proline; Quinolines; Simeprevir; Sofosbuvir; Sulfonamides; Thiazoles; Time Factors; Uridine Monophosphate | 2014 |
Treating HCV in HIV 2013: on the cusp of change.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Coinfection; Drug Interactions; Drug Therapy, Combination; Hepacivirus; Hepatitis C; HIV Infections; Humans; Imidazoles; Leucine; Oligopeptides; Proline; Pyrrolidines; Quinolines; Sofosbuvir; Thiazoles; Treatment Outcome; Uridine Monophosphate; Valine | 2014 |
Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir.
Topics: Aminoisobutyric Acids; Antiviral Agents; Clinical Trials as Topic; Drug Approval; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Leucine; Oligopeptides; Proline; Quinolines; Simeprevir; Sofosbuvir; Sulfonamides; Thiazoles; Time Factors; Uridine Monophosphate | 2014 |
HCV direct-acting antiviral agents: the best interferon-free combinations.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Clinical Trials as Topic; Disease Eradication; Drug Discovery; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Interferon-alpha; Isoquinolines; Leucine; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Pyrrolidines; Quinolines; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Thiazoles; Uridine Monophosphate; Valine; Viral Nonstructural Proteins; Virus Replication | 2014 |
Hepatitis C treatment: an incipient therapeutic revolution.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Molecular Targeted Therapy; Oligopeptides; Proline; Protease Inhibitors; Sofosbuvir; Uridine Monophosphate | 2014 |
Interferon-free strategies with a nucleoside/nucleotide analogue.
Topics: Animals; Antiviral Agents; Benzimidazoles; Drug Design; Drug Resistance, Viral; Fluorenes; Hepacivirus; Hepatitis C; Humans; Interferons; Molecular Targeted Therapy; Nucleosides; Nucleotides; Protease Inhibitors; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Nonstructural Proteins | 2014 |
Hepatitis C.
Topics: Adult; Age Distribution; Anti-HIV Agents; Communicable Disease Control; Disease Management; Female; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Incidence; Liver Cirrhosis; Male; Middle Aged; Needs Assessment; Prisoners; Prisons; Ribavirin; Risk Assessment; Sex Distribution; Simeprevir; Sofosbuvir; Sulfonamides; Telemedicine; Treatment Outcome; United States; Uridine Monophosphate; Young Adult | 2014 |
Daclatasvir for the treatment of hepatitis C virus infection.
Topics: Administration, Oral; Antiviral Agents; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Hepatitis C; Humans; Imidazoles; Isoquinolines; Pyrrolidines; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate; Valine | 2014 |
Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?
Topics: 2-Naphthylamine; Amides; Anilides; Antiviral Agents; Benzofurans; Carbamates; Clinical Trials as Topic; Cyclopropanes; Disease Eradication; Drug Combinations; Hepacivirus; Hepatitis C; Humans; Imidazoles; Isoquinolines; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Uracil; Uridine Monophosphate; Valine | 2014 |
Sofosbuvir (Sovaldi) for the treatment of hepatitis C.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Humans; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins | 2014 |
Antiviral treatment of hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate; Viral Nonstructural Proteins | 2014 |
Sofosbuvir, a novel nucleotide analogue inhibitor used for the treatment of hepatitis C virus.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Nonstructural Proteins | 2014 |
Recent advances and future directions in the management of hepatitis C infections.
Topics: Animals; Antiviral Agents; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Failure; Uridine Monophosphate | 2015 |
Recent advances in the treatment of hepatitis C.
Topics: Animals; Antiviral Agents; Carrier Proteins; Clinical Trials as Topic; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Intracellular Signaling Peptides and Proteins; Ribavirin; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins | 2014 |
Hepatitis C management in post-transplant patients.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Fluorenes; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Oligopeptides; Polyethylene Glycols; Proline; Pyrrolidines; Recombinant Proteins; Recurrence; Ribavirin; Risk Factors; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate; Valine; Viral Load | 2015 |
Sofosbuvir as backbone of interferon free treatments.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis D, Chronic; Humans; Interferons; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2014 |
Efficacy of sofosbuvir-based therapies in HIV/HCV infected patients and persons who inject drugs.
Topics: Antiviral Agents; Coinfection; Drug Therapy, Combination; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Sofosbuvir; Substance Abuse, Intravenous; Uridine Monophosphate | 2014 |
How to optimize current therapy in hepatitis C virus genotype 1 patients. Predictors of response to interferon-based therapy with second wave direct acting antivirals.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Interferon-alpha; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate; Valine | 2015 |
Safety analysis of sofosbuvir and ledipasvir for treating hepatitis C.
Topics: Antiviral Agents; Benzimidazoles; Drug Approval; Drug Combinations; Drug Interactions; Fluorenes; Hepatitis C; Humans; Sofosbuvir; Uridine Monophosphate | 2015 |
The hepatitis C revolution part 2: difficult-to-treat groups and experimental approaches.
Topics: Antiviral Agents; Benzimidazoles; Coinfection; Drug Design; Drug Resistance, Viral; Fluorenes; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Sofosbuvir; Uridine Monophosphate | 2015 |
Pharmacokinetics and pharmacodynamics of sofosbuvir and ledipasvir for the treatment of hepatitis C.
Topics: Animals; Antiviral Agents; Benzimidazoles; Dose-Response Relationship, Drug; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Sofosbuvir; Time Factors; Treatment Outcome; Uridine Monophosphate | 2017 |
The HCV NS5B nucleoside and non-nucleoside inhibitors.
Topics: Antiviral Agents; Clinical Trials as Topic; Deoxycytidine; Guanosine Monophosphate; Hepatitis C; Humans; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins | 2011 |
Interferon free hepatitis C treatment regimens: the beginning of another era.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferon-alpha; Protease Inhibitors; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2012 |
Update on combinations of DAAs with and without pegylated-interferon and ribavirin: triple and quadruple therapy more than doubles SVR.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferons; Peptides, Cyclic; Phosphinic Acids; Polyethylene Glycols; Protease Inhibitors; Quinolines; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2013 |
Nucleoside/nucleotide analogue polymerase inhibitors in development.
Topics: Cytidine; Deoxycytidine; Drugs, Investigational; Enzyme Inhibitors; Hepacivirus; Hepatitis C; Humans; Protein Conformation; RNA-Dependent RNA Polymerase; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins | 2013 |
18 trial(s) available for uridine monophosphate and Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted
| Article | Year |
|---|---|
Efficacy of Sofosbuvir plus Ledipasvir in Egyptian patients with COVID-19 compared to standard treatment: a randomized controlled trial.
Topics: Antiviral Agents; Benzimidazoles; COVID-19 Drug Treatment; Drug Therapy, Combination; Egypt; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; SARS-CoV-2; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2022 |
Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Opiate Substitution Treatment; Outcome Assessment, Health Care; Pharmacists; Pyrrolidines; Scotland; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate; Valine | 2020 |
Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; New Zealand; Non-Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Ribavirin; Safety; Sofosbuvir; Treatment Outcome; United States; Uridine Monophosphate; Viral Load | 2020 |
Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial.
Topics: Acute Disease; Adult; Anti-HIV Agents; Antiviral Agents; Benzimidazoles; Coinfection; Drug Administration Schedule; Fluorenes; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Male; Middle Aged; Pilot Projects; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Load | 2017 |
Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Coinfection; DNA, Viral; Female; Fluorenes; Hepacivirus; Hepatitis B; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis C; Humans; Male; Middle Aged; Prospective Studies; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Taiwan; Time Factors; Treatment Outcome; Uridine Monophosphate; Viral Load | 2018 |
Treatment as Prevention for Hepatitis C (TraP Hep C) - a nationwide elimination programme in Iceland using direct-acting antiviral agents.
Topics: Antiviral Agents; Benzimidazoles; Carcinoma, Hepatocellular; Drug Therapy, Combination; Fluorenes; Hepatitis C; Humans; Iceland; Incidence; Liver Cirrhosis; Liver Neoplasms; Mass Screening; Needle-Exchange Programs; Population Surveillance; Ribavirin; Sofosbuvir; Substance Abuse, Intravenous; Uridine Monophosphate | 2018 |
Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate.
Topics: Adenine; Adult; Antiviral Agents; Benzimidazoles; Coinfection; Drug Interactions; Fluorenes; Hepatitis C; HIV Infections; Humans; Male; Middle Aged; Organophosphates; Ribavirin; Sofosbuvir; Tenofovir; Uridine Monophosphate | 2018 |
Hepatitis C virus serologic relapse after treatment with direct-acting antivirals is dependent on viral RNA levels in peripheral blood mononuclear cells and the grade of liver cirrhosis.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C; Humans; Leukocytes, Mononuclear; Liver Cirrhosis; Male; Middle Aged; Recurrence; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Young Adult | 2018 |
Randomized feasibility trial of directly observed versus unobserved hepatitis C treatment with ledipasvir-sofosbuvir among people who inject drugs.
Topics: Adult; Benzimidazoles; Female; Fluorenes; Hepatitis C; Humans; Male; Middle Aged; Prevalence; San Francisco; Sofosbuvir; Substance Abuse, Intravenous; Uridine Monophosphate | 2019 |
Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals.
Topics: Acute Disease; Administration, Oral; Adult; Antiviral Agents; Benzimidazoles; Cohort Studies; Drug Administration Schedule; Fluorenes; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferons; Male; Middle Aged; Ribavirin; Sexual and Gender Minorities; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Viral Load | 2019 |
Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial.
Topics: Antiviral Agents; Body Weight; Female; Hepacivirus; Hepatitis C; Humans; Interferons; Interleukins; Male; Middle Aged; Prognosis; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Load | 2013 |
All-oral therapy with nucleotide inhibitors sofosbuvir and GS-0938 for 14 days in treatment-naive genotype 1 hepatitis C (nuclear).
Topics: Administration, Oral; Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Load; Young Adult | 2013 |
Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Enzyme Inhibitors; Fatigue; Female; Fluorenes; Furans; Genotype; Headache; Hepacivirus; Hepatitis C; Humans; Incidence; Male; Middle Aged; Nausea; Sofosbuvir; Thiophenes; Treatment Outcome; Uridine Monophosphate; Viral Nonstructural Proteins | 2014 |
Analysis of hepatitis C viral kinetics during administration of two nucleotide analogues: sofosbuvir (GS-7977) and GS-0938.
Topics: Adult; Antiviral Agents; Cyclic P-Oxides; Double-Blind Method; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Nucleosides; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Viral Load; Young Adult | 2014 |
Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study.
Topics: Aged; Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Drug Therapy, Combination; Europe; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; New Zealand; Pilot Projects; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Time Factors; Treatment Outcome; United States; Uridine Monophosphate; Viral Load; Waiting Lists | 2015 |
Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.
Topics: Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; New Zealand; Pilot Projects; Prospective Studies; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Spain; Time Factors; Treatment Outcome; United States; Uridine Monophosphate; Viral Load | 2015 |
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.
Topics: Administration, Oral; Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Sofosbuvir; Time Factors; Uridine Monophosphate; Valine; Young Adult | 2015 |
Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir.
Topics: Adult; Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Viral Nonstructural Proteins | 2016 |
107 other study(ies) available for uridine monophosphate and Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted
| Article | Year |
|---|---|
Mechanism of activation of beta-D-2'-deoxy-2'-fluoro-2'-c-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase.
Topics: Antiviral Agents; Catalysis; Deoxycytidine; Hepacivirus; Hepatitis C; Humans; Mutation; Phosphorylation; RNA-Dependent RNA Polymerase; RNA, Viral; Structure-Activity Relationship; Viral Nonstructural Proteins; Virus Replication | 2007 |
Trends in Renal Function Among Heart Transplant Recipients of Donor-Derived Hepatitis C Virus.
Topics: Adult; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; Heart Transplantation; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Kidney Diseases; Male; Middle Aged; Sofosbuvir; Sustained Virologic Response; Tissue Donors; Transplant Recipients; Uridine Monophosphate | 2020 |
Successful evolution of morphea after hepatitis C virus eradication with direct-acting antiviral agent treatment.
Topics: Adult; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Scleroderma, Localized; Sofosbuvir; Thigh; Uridine Monophosphate | 2019 |
Hepatitis C virus eradication with directly acting antivirals improves health-related quality of life and psychological symptoms.
Topics: Aged; Antiviral Agents; Anxiety; Benzimidazoles; Depression; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Psychological Tests; Quality of Life; Self Report; Severity of Illness Index; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2019 |
The paediatric population: the forgotten element to eliminating hepatitis C virus.
Topics: Adolescent; Antiviral Agents; Benzimidazoles; Child; Chronic Disease; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Infectious Disease Transmission, Vertical; Liver Diseases; Male; Prevalence; Risk Factors; Sofosbuvir; Uridine Monophosphate; Young Adult | 2020 |
Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Coinfection; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; United States; Uridine Monophosphate; Viral Load | 2020 |
Hepatitis C virus treatment response to ledipasvir/sofosbuvir among patients coinfected with HIV and HCV: Real world data in a black population.
Topics: Antiviral Agents; Benzimidazoles; Black or African American; Coinfection; Female; Fluorenes; Hepacivirus; Hepatitis C; HIV Infections; Humans; Male; Middle Aged; New Jersey; Retrospective Studies; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2020 |
English hepatitis C registry data show high response rates to directly acting anti-virals, even if treatment is not completed.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Drug Combinations; England; Female; Fluorenes; Hepatitis C; Humans; Imidazoles; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Quinoxalines; Registries; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Uridine Monophosphate; Valine; Young Adult | 2020 |
Beta-thalassemia major alters sofosbuvir/ledipasvir exposure in Hepatitis C virus infected adolescent patients.
Topics: Adolescent; Adult; Antiviral Agents; Benzimidazoles; beta-Thalassemia; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Pharmaceutical Preparations; Prospective Studies; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2021 |
Exploring the Case for Eminent Domain of Hepatitis C Virus Treatment Patents.
Topics: Antiviral Agents; Benzimidazoles; Budgets; Drug Combinations; Drug Costs; Drug Industry; Fluorenes; Hepatitis C; Humans; Patents as Topic; Public Health; Sofosbuvir; United States; Uridine Monophosphate | 2017 |
Kidney transplant recipients with hepatitis C virus experienced 100% sustained virologic response at 12 weeks when treated with sofosbuvir-ledipasvir.
Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Hepatitis C; Humans; Kidney Transplantation; Postoperative Complications; Randomized Controlled Trials as Topic; Sofosbuvir; Sustained Virologic Response; Time Factors; Uridine Monophosphate | 2017 |
Chemical Analysis of Counterfeit Hepatitis C Drug Found in Japan.
Topics: Antiviral Agents; Benzimidazoles; Chromatography, Liquid; Counterfeit Drugs; Drugs, Chinese Herbal; Ephedrine; Fluorenes; Gas Chromatography-Mass Spectrometry; Glycyrrhizic Acid; Hepatitis C; Japan; Magnetic Resonance Spectroscopy; Mass Spectrometry; Sofosbuvir; Tablets; Uridine Monophosphate; Vitamins | 2017 |
Two Antiviral Drugs Approved For Adolescents With HCV.
Topics: Adolescent; Antiviral Agents; Benzimidazoles; Child; Fluorenes; Hepacivirus; Hepatitis C; Humans; Infant, Newborn; Sofosbuvir; Uridine Monophosphate | 2017 |
Treatment of Patients With Hepatitis C Virus Infection With Ledipasvir-Sofosbuvir in the Liver Transplant Setting.
Topics: Administration, Oral; Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Prospective Studies; Ribavirin; Saudi Arabia; Sofosbuvir; Sustained Virologic Response; Tablets; Time Factors; Treatment Outcome; Uridine Monophosphate; Viral Load | 2017 |
Clearance of Hepatitis C Virus Prior to Lung Transplantation: A Case Report.
Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Hepacivirus; Hepatitis C; Humans; Lung Transplantation; Male; Middle Aged; Preoperative Care; Sofosbuvir; Uridine Monophosphate | 2017 |
Administration of crushed ledipasvir-sofosbuvir tablets via gastrostomy button in a patient coinfected with HIV and hepatitis C virus.
Topics: Anti-HIV Agents; Benzimidazoles; Female; Fluorenes; Gastrostomy; Hepatitis C; HIV Infections; Humans; Sofosbuvir; Tablets; Treatment Outcome; Uridine Monophosphate; Viral Load; Young Adult | 2017 |
Hepatitis C Treatment with Sofosbuvir and Ledipasvir Accompanied by Immediate Improvement in Hemoglobin A1c.
Topics: Aged; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Glycated Hemoglobin; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Pilot Projects; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate | 2017 |
Sexual Dysfunction in a Patient Taking Ledipasvir/Sofosbuvir for the Treatment of Hepatitis C: A Case Report.
Topics: Adult; Antiviral Agents; Benzimidazoles; Drug-Related Side Effects and Adverse Reactions; Fluorenes; Hepatitis C; Humans; Male; Sexual Dysfunction, Physiological; Sofosbuvir; Uridine Monophosphate | 2019 |
Interferon-free treatments in patients with hepatitis C genotype 3 infection in a tertiary hospital.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Cohort Studies; Drug Combinations; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Tertiary Care Centers; Uridine Monophosphate | 2018 |
The safety and efficacy of ledipasvir/sofosbuvir with or without ribavirin in the treatment of orthotopic liver transplant recipients with recurrent hepatitis C: real-world data.
Topics: Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Recurrence; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Uridine Monophosphate; Virus Activation | 2018 |
Take a Bow, Pharma, for the Hepatitis C Drugs.
Topics: Antiviral Agents; Benzimidazoles; Drug Industry; Fluorenes; Hepatitis C; Humans; Sofosbuvir; United States; Uridine Monophosphate | 2018 |
Direct-Acting Antiviral Therapy for Hepatitis C Infection in a Large Immigrant Community.
Topics: Africa, Eastern; Age Factors; Aged; Antiviral Agents; Benzimidazoles; Emigrants and Immigrants; Ethnicity; Female; Fluorenes; Genotype; Hepatitis C; Humans; Male; Middle Aged; Middle East; Retrospective Studies; Severity of Illness Index; Sex Factors; Socioeconomic Factors; Sofosbuvir; Sustained Virologic Response; Treatment Failure; United States; Uridine Monophosphate | 2019 |
Ledipasvir/Sofosbuvir Effectively Treats Hepatitis C Virus Infections in an Underserved Population.
Topics: Antiviral Agents; Benzimidazoles; Drug Monitoring; Female; Fluorenes; Genes, Viral; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Patient Compliance; Prevalence; Sofosbuvir; Uridine Monophosphate; Vulnerable Populations | 2018 |
Successful Treatment With Ledipasvir/Sofosbuvir in an Infant With Severe Combined Immunodeficiency Caused by Adenosine Deaminase Deficiency With HCV Allowed Gene Therapy with Strimvelis.
Topics: Adenosine Deaminase; Agammaglobulinemia; Antiviral Agents; Benzimidazoles; Fluorenes; Genetic Therapy; Hepatitis C; Humans; Infant; Male; Severe Combined Immunodeficiency; Sofosbuvir; Uridine Monophosphate | 2018 |
Clinical significance of detectable and quantifiable HCV RNA at the end of treatment with ledipasvir/sofosbuvir in GT1 patients.
Topics: Antiviral Agents; Benzimidazoles; Female; Fluorenes; Germany; Hepacivirus; Hepatitis C; Humans; Male; Registries; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Viral Load | 2018 |
Lack of Patient Compliance in Real-World Practice Negatively Affects Sustained Viral Response Rates to Direct Acting Agent Therapy for Hepatitis C.
Topics: Antiviral Agents; Benzimidazoles; Drug Monitoring; Female; Fluorenes; Genes, Viral; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Patient Compliance; Patient Dropouts; Patient Education as Topic; Patient Medication Knowledge; Retrospective Studies; Sofosbuvir; Sustained Virologic Response; United States; Uridine Monophosphate | 2018 |
Multicenter Experience using Ledipasvir/Sofosbuvir ± RBV to Treat HCV GT 1 Relapsers after Simeprevir and Sofosbuvir Treatment.
Topics: Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Recurrence; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; United States; Uridine Monophosphate; Viral Load | 2018 |
Effectiveness of 8 weeks of ledipasvir/sofosbuvir for hepatitis C in HCV-HIV-coinfected patients.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C; HIV Infections; Humans; Male; Middle Aged; Retrospective Studies; Sofosbuvir; Uridine Monophosphate | 2019 |
Eight-Week Hepatitis C Treatment with New Direct Acting Antivirals Has a Better Safety Profile While Being Effective in the Treatment-Naïve Geriatric Population Without Liver Cirrhosis and Hepatitis C Virus-RNA < 6 Million IU/mL.
Topics: Age Factors; Aged; Antiviral Agents; Benzimidazoles; California; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Retrospective Studies; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate; Viral Load | 2018 |
Evidence of HCV recovery after therapy of hepatitis C virus infection by direct acting antivirals.
Topics: Adult; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Kidney; Living Donors; Male; Middle Aged; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Viral Load | 2019 |
Gilead injects own generics into shrinking HCV drug market.
Topics: Antiviral Agents; Benzimidazoles; Biotechnology; Drug Costs; Drug Industry; Drugs, Generic; Fluorenes; Hepatitis C; Humans; Sofosbuvir; United States; Uridine Monophosphate | 2018 |
Early sofosbuvir-ledipasvir treatment for acute HCV infection induced severe immune thrombocytopenia - a case report.
Topics: Acute Disease; Antiviral Agents; Benzimidazoles; Early Medical Intervention; Fluorenes; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Severity of Illness Index; Sofosbuvir; Time Factors; Uridine Monophosphate | 2018 |
Drug-Drug Interactions in Children and Adolescents Receiving Ledipasvir/Sofosbuvir for the Treatment of Hepatitis C Virus Infection.
Topics: Adolescent; Antiviral Agents; Benzimidazoles; Child; Drug Interactions; Female; Fluorenes; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Risk Assessment; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2019 |
Ledipasvir and Sofosbuvir for Acute Hepatitis C Virus Monoinfection Associated with a High Risk of Acute Liver Failure.
Topics: Acute Disease; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C; Humans; Liver Failure, Acute; Male; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate | 2019 |
Targeted drugs to tackle hepatitis C.
Topics: Age Factors; Carrier State; Clinical Trials, Phase III as Topic; Drug Approval; Hepacivirus; Hepatitis C; Humans; Male; Mass Screening; Middle Aged; Molecular Targeted Therapy; Risk Assessment; Sofosbuvir; Uridine Monophosphate | 2013 |
Trials wrap on interferon-free hepatitis C regimen.
Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Hepatitis C; Humans; Interferons; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2013 |
All-oral HCV therapies near approval.
Topics: Administration, Oral; Animals; Drug Approval; Hepacivirus; Hepatitis C; Humans; Sofosbuvir; Uridine Monophosphate; Viral Hepatitis Vaccines | 2013 |
Sofosbuvir with ribavirin is safe and effective in hepatitis C genotype 1 with unfavourable pretreatment characteristics.
Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C; Humans; Male; Ribavirin; Uridine Monophosphate | 2014 |
Pharmaceuticals. Advocates protest the cost of a hepatitis C cure.
Topics: Antiviral Agents; Consumer Advocacy; Cost of Illness; Drug Approval; Drugs, Generic; Hepacivirus; Hepatitis C; Humans; Prevalence; Sofosbuvir; United States; United States Food and Drug Administration; Uridine Monophosphate | 2013 |
Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries.
Topics: Aminoisobutyric Acids; Anti-HIV Agents; Antiviral Agents; Carbamates; Developing Countries; Drug Industry; Drug Therapy, Combination; Health Services Accessibility; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Leucine; Oligopeptides; Proline; Pyrrolidines; Quinolines; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Thiazoles; Uridine Monophosphate; Valine | 2014 |
FDA approvals usher in the post-interferon era in HCV.
Topics: Drug Approval; Drug Industry; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Simeprevir; Sofosbuvir; Sulfonamides; United States; United States Food and Drug Administration; Uridine Monophosphate | 2014 |
Screening urged for hepatitis C but drug costs are prohibitive.
Topics: Antiviral Agents; Canada; Drug Costs; Hepatitis C; Humans; Mass Screening; Sofosbuvir; Uridine Monophosphate | 2014 |
Hepatitis C treatment & management.
Topics: Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Liver Transplantation; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Recurrence; Ribavirin; Sofosbuvir; Time Factors; Uridine Monophosphate | 2014 |
Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens.
Topics: Adult; Antiviral Agents; Chronic Disease; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2014 |
Hepatitis C could be virtually eliminated by 2030, experts believe.
Topics: Antiviral Agents; Disease Eradication; Hepatitis C; Humans; Sofosbuvir; Uridine Monophosphate | 2014 |
Hepatitis C drugs not reaching poor.
Topics: Anti-HIV Agents; Antiviral Agents; Developing Countries; Drug Costs; Hepatitis C; Humans; Sofosbuvir; Uridine Monophosphate | 2014 |
Hepatitis C: Treatment triumphs.
Topics: Administration, Oral; Antiviral Agents; Drug Resistance, Viral; Hepacivirus; Hepatitis C; Humans; Interferon Type I; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2014 |
Sovaldi makes blockbuster history, ignites drug pricing unrest.
Topics: Drug Industry; Health Care Costs; Hepatitis C; Income; Sofosbuvir; United States; Uridine Monophosphate | 2014 |
WHO issues guidelines on HCV amid drug cost controversy.
Topics: Antiviral Agents; Drug Costs; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Practice Guidelines as Topic; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate; World Health Organization | 2014 |
Elimination on the agenda for hepatitis C.
Topics: Antiviral Agents; Disease Eradication; Global Health; Hepatitis C; Humans; Injections; Interferons; Ribavirin; Sofosbuvir; Substance Abuse, Intravenous; Uridine Monophosphate | 2014 |
Sofosbuvir for the treatment of hepatitis C virus infection.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Humans; Sofosbuvir; Uridine Monophosphate | 2015 |
Medicine. Hepatitis C can be cured globally, but at what cost?
Topics: Antiviral Agents; Developing Countries; Drug Costs; Drugs, Generic; Global Health; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate | 2014 |
Payers consider waiting out budget-busting hepatitis C drug.
Topics: Antiviral Agents; Hepatitis C; Humans; Managed Care Programs; Medicaid; Politics; Product Surveillance, Postmarketing; Sofosbuvir; United States; Uridine Monophosphate | 2014 |
Bridging all oral DAA therapy from wait time to post-liver transplant to improve HCV eradication?
Topics: Administration, Oral; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2015 |
Characterization of hepatitis C virus intergenotypic recombinant strains and associated virological response to sofosbuvir/ribavirin.
Topics: Adult; Aged; Antiviral Agents; Female; Genome, Viral; Genotyping Techniques; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Phylogeny; Recombination, Genetic; Ribavirin; Sequence Analysis, RNA; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Nonstructural Proteins | 2015 |
US health insurers say Gilead hepatitis C drug too costly.
Topics: Antiviral Agents; Health Care Costs; Hepatitis C; Humans; Insurance Carriers; Sofosbuvir; United States; Uridine Monophosphate | 2014 |
Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir.
Topics: Amino Acid Substitution; Clinical Trials, Phase III as Topic; Computational Biology; Drug Resistance, Viral; Hepacivirus; Hepatitis C; Humans; Sequence Analysis, RNA; Sofosbuvir; United States; United States Food and Drug Administration; Uridine Monophosphate; Viral Nonstructural Proteins | 2015 |
Successful treatment of fibrosing cholestatic hepatitis with pegylated interferon, ribavirin and sofosbuvir after a combined kidney-liver transplantation.
Topics: Aged; Antiviral Agents; Drug Combinations; Hepatitis C; Humans; Interferon-alpha; Kidney Transplantation; Liver Transplantation; Male; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2015 |
Sofosbuvir and ribavirin use in wait-listed patients with hepatitis C should be selective.
Topics: Administration, Oral; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C; Humans; Recurrence; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Waiting Lists | 2015 |
The solid-gold wonder drug. A long, difficult and costly research effort gives doctors a new cure for hepatitis C.
Topics: Drug Combinations; Drug Costs; Hepatitis C; Humans; Sofosbuvir; United States; United States Food and Drug Administration; Uridine Monophosphate | 2014 |
Guideline: New HCV drugs should go to sickest patients.
Topics: Antiviral Agents; Drug Costs; Hepatitis C; Humans; Patient Selection; Practice Guidelines as Topic; Societies, Medical; Sofosbuvir; United States; Uridine Monophosphate | 2014 |
A treatment revolution for those who can afford it? Hepatitis C treatment: new medications, profits and patients.
Topics: Antiviral Agents; Healthcare Disparities; Hepatitis C; Humans; Sofosbuvir; Substance Abuse, Intravenous; Uridine Monophosphate | 2014 |
Mutant Ninja viruses.
Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C; Humans; Male; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2015 |
Editorial: patients' preferences and health utility assessment in those with HCV treated with sofosbuvir - stating the obvious?
Topics: Antiviral Agents; Hepatitis C; Humans; Patient Acceptance of Health Care; Patient Preference; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2014 |
Editorial: patients' preferences and health utility assessment in those with HCV treated with sofosbuvir - stating the obvious? Authors' reply.
Topics: Antiviral Agents; Hepatitis C; Humans; Patient Acceptance of Health Care; Patient Preference; Uridine Monophosphate | 2014 |
Sovaldi dilemma likely to get worse.
Topics: Antiviral Agents; Benzimidazoles; Drug Combinations; Fluorenes; Hepatitis C; Humans; Prescription Fees; Sofosbuvir; United States; Uridine Monophosphate | 2014 |
The uses and abuses of cost-effectiveness analysis.
Topics: Cost Savings; Cost-Benefit Analysis; Drug Costs; Hepatitis C; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Sofosbuvir; Uridine Monophosphate | 2014 |
New nucleotide polymerase inhibitors to rapidly permit hematopoietic stem cell donation from a positive HCV-RNA donor.
Topics: Adult; Female; Hematopoietic Stem Cell Transplantation; Hepacivirus; Hepatitis C; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; RNA, Viral; Siblings; Sofosbuvir; Tissue Donors; Uridine Monophosphate | 2014 |
Sofosbuvir, simeprevir, and ribavirin for the treatment of hepatitis C virus recurrence in human immunodeficiency virus/hepatitis C virus-coinfected liver transplant recipients.
Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Immunosuppressive Agents; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate | 2015 |
Treatment of HCV prior to liver transplantation to prevent HCV recurrence - wise or wasteful?
Topics: Administration, Oral; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C; Humans; Liver Cirrhosis; Liver Transplantation; Recurrence; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2015 |
Sofosbuvir treatment in the pre and post liver transplantation phase: the sooner, the better.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Female; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2015 |
Cost-effectiveness model for hepatitis C screening and treatment: Implications for Egypt and other countries with high prevalence.
Topics: Antiviral Agents; Cost-Benefit Analysis; Decision Trees; Disease Progression; Drug Therapy, Combination; Egypt; Enzyme-Linked Immunosorbent Assay; Hepatitis C; Humans; Incidence; Interferons; Markov Chains; Mass Screening; Models, Economic; Polymerase Chain Reaction; Prevalence; Quality of Life; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2015 |
Perspective: incision revision.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B; Hepatitis C; Humans; Liver Neoplasms; Sofosbuvir; Uridine Monophosphate | 2014 |
Haemophilia-related outcome after liver transplantation and treatment with sofosbuvir/ribavirin in a HCV-HIV coinfected man with liver failure and hepatocellular carcinoma.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Carcinoma, Hepatocellular; Coinfection; Hemophilia A; Hepatitis C; HIV Infections; Humans; Liver Failure; Liver Transplantation; Male; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2015 |
Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant.
Topics: Aged; Antiviral Agents; Female; Genotype; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Immunosuppression Therapy; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Recurrence; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate | 2015 |
HIV-hepatitis C co-infection.
Topics: Antiviral Agents; Carbamates; Coinfection; Hepatitis C; HIV Infections; Humans; Imidazoles; Pyrrolidines; Randomized Controlled Trials as Topic; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Valine | 2015 |
[Joint opinion of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) and the German Society for Internal Medicine (DGIM) to Daclatasvir-benefit assessment according to § 35a SGB V the G-BA].
Topics: Anti-HIV Agents; Carbamates; Drug Combinations; Gastroenterology; Germany; Hepatitis C; Imidazoles; Internal Medicine; Pyrrolidines; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Valine | 2015 |
Regression of an HCV-associated disseminated marginal zone lymphoma under IFN-free antiviral treatment.
Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C; Humans; Lymphoma, B-Cell, Marginal Zone; Middle Aged; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2015 |
HCV/HIV Coinfection: A New Treatment Paradigm.
Topics: Antiviral Agents; Coinfection; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Male; Ribavirin; Uridine Monophosphate | 2015 |
King of the pills.
Topics: Anti-HIV Agents; Chemistry, Organic; Drug Discovery; Hepatitis C; History, 20th Century; History, 21st Century; Sofosbuvir; Uridine Monophosphate | 2015 |
Dare to refuse the exorbitant price of Sovaldi!
Topics: Antiviral Agents; Drug Costs; Drug Industry; Hepatitis C; Humans; Sofosbuvir; Uridine Monophosphate | 2014 |
Campaigners challenge patent applications for hepatitis C drug in five countries.
Topics: Antiviral Agents; Argentina; Brazil; China; Drug Costs; Drugs, Generic; Hepatitis C; Humans; Legislation, Drug; Patents as Topic; Russia; Sofosbuvir; Ukraine; Uridine Monophosphate | 2015 |
China rejects patent on hepatitis C drug sofosbuvir.
Topics: Antiviral Agents; China; Cost Control; Drug Costs; Hepatitis C; Humans; Product Surveillance, Postmarketing; Sofosbuvir; Uridine Monophosphate | 2015 |
Lawsuit seeks access to data from hepatitis C drug trial.
Topics: Access to Information; Antiviral Agents; Benzimidazoles; Clinical Trials as Topic; Drug Approval; Fluorenes; Hepatitis C; Humans; Product Surveillance, Postmarketing; Research Design; Sofosbuvir; United States; United States Food and Drug Administration; Uridine Monophosphate | 2015 |
[Joint Statement of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) and the German Society for Internal Medicine (DGIM) to Ledipasvir / sofosbuvir-benefit assessment according to § 35a SGB V the G-BA].
Topics: Antiviral Agents; Benzimidazoles; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Evidence-Based Medicine; Fluorenes; Gastroenterology; Germany; Hepatitis C; HIV Infections; Humans; Practice Guidelines as Topic; Risk Assessment; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2015 |
Sofosbuvir (Sovaldi) for hepatitis C virus.
Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Approval; Hepacivirus; Hepatitis C; Humans; Sofosbuvir; United States; United States Food and Drug Administration; Uridine Monophosphate | 2015 |
Recombinant hepatitis C viruses that might hamper accurate genotype classification and choice of treatment with direct-acting agents, southeastern France.
Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C; Humans; Male; Ribavirin; Uridine Monophosphate | 2016 |
The safety and efficacy of ledipasvir/sofosbuvir for the treatment of a nosocomial outbreak of HCV in patients with significant cardiovascular disease.
Topics: Aged; Antiviral Agents; Benzimidazoles; Cardiovascular Diseases; Cross Infection; Disease Outbreaks; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Pilot Projects; Sofosbuvir; Uridine Monophosphate | 2016 |
Harvoni (ledipasvir and sofosbuvir) for hepatitis C.
Topics: Antiviral Agents; Benzimidazoles; Contraindications; Drug Interactions; Fluorenes; Hepatitis C; Humans; Nurse Practitioners; Patient Education as Topic; Practice Guidelines as Topic; Sofosbuvir; Uridine Monophosphate | 2015 |
Liver failure in human immunodeficiency virus - Hepatitis C virus coinfection treated with sofosbuvir, ledipasvir and antiretroviral therapy.
Topics: Antiviral Agents; Coinfection; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Liver Failure; Sofosbuvir; Uridine Monophosphate | 2016 |
Successful therapy with Ledipasvir/Sofosbuvir for hepatitis C reactivation in a hematopoietic stem cell transplant recipient.
Topics: Anemia, Aplastic; Benzimidazoles; Female; Fluorenes; Hematopoietic Stem Cell Transplantation; Hepacivirus; Hepatitis C; Humans; Middle Aged; Myelodysplastic Syndromes; Sofosbuvir; Transplant Recipients; Treatment Outcome; Uridine Monophosphate; Virus Activation | 2016 |
New Indications for Harvoni.
Topics: Antiviral Agents; Benzimidazoles; Coinfection; Drug Approval; Fluorenes; Hepacivirus; Hepatitis C; HIV Infections; Humans; Liver Cirrhosis; Sofosbuvir; United States; United States Food and Drug Administration; Uridine Monophosphate | 2016 |
Real-world effectiveness of ledipasvir/sofosbuvir in 4,365 treatment-naive, genotype 1 hepatitis C-infected patients.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Cohort Studies; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2016 |
Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis.
Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Health Expenditures; Hepatitis C; Humans; Prescription Fees; Sofosbuvir; Uridine Monophosphate | 2016 |
Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Retrospective Studies; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; United States; United States Department of Veterans Affairs; Uracil; Uridine Monophosphate; Valine | 2016 |
Economic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cost-Benefit Analysis; Cyclopropanes; Drug Combinations; Female; Fluorenes; Health Services Accessibility; Hepacivirus; Hepatitis C; HIV Protease Inhibitors; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Markov Chains; Medicaid; Middle Aged; Proline; Ritonavir; Severity of Illness Index; Sofosbuvir; Sulfonamides; United States; Uracil; Uridine Monophosphate; Valine | 2016 |
[Not Available].
Topics: AIDS-Related Opportunistic Infections; Benzimidazoles; Cross-Cultural Comparison; Cross-Sectional Studies; Developing Countries; Drug Costs; Europe; Fluorenes; Hepatitis B; Hepatitis C; HIV Infections; Humans; Medical Tourism; Sofosbuvir; United States; Uridine Monophosphate | 2016 |
New Hepatitis C Drugs Are Very Costly And Unavailable To Many State Prisoners.
Topics: Adult; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepatitis C; Humans; Male; North Carolina; Prisoners; Prisons; Retrospective Studies; Sofosbuvir; State Government; United States; Uridine Monophosphate | 2016 |
Psoriasis as a Manifestation of an Immune Reconstitution in Two Patients with Hepatitis C Treated with Ledipasvir/Sofosbuvir.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Combined Modality Therapy; Dermatologic Agents; Disease Progression; Fluorenes; Hepatitis C; Humans; Male; Psoriasis; Risk Factors; Severity of Illness Index; Sofosbuvir; Treatment Outcome; Ultraviolet Therapy; Uridine Monophosphate | 2017 |
Sofosbuvir/ledipasvir and ribavirin tolerability and efficacy in pediatric liver transplant recipients.
Topics: Adolescent; Antiviral Agents; Benzimidazoles; Biliary Atresia; Budd-Chiari Syndrome; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Infant; Liver; Liver Cirrhosis; Liver Transplantation; Male; Recurrence; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate | 2017 |
Treatment of de novo hepatitis C virus-related fibrosing cholestatic hepatitis after orthotopic heart transplantation by ledipasvir and sofosbuvir.
Topics: Acute Kidney Injury; Antiviral Agents; Benzimidazoles; Fluorenes; Heart Failure; Heart Transplantation; Hepatic Encephalopathy; Hepatitis C; Humans; Liver Function Tests; Male; Middle Aged; Myocardial Infarction; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2017 |
Effectiveness of All-Oral Antiviral Regimens in 996 Human Immunodeficiency Virus/Hepatitis C Virus Genotype 1-Coinfected Patients Treated in Routine Practice.
Topics: Administration, Oral; Aged; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Coinfection; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Practice Patterns, Physicians'; Proline; Registries; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate; Valine; Veterans | 2017 |
Effectiveness of interferon-free therapy for the treatment of HCV-patients with compensated cirrhosis treated through the Irish early access program.
Topics: Adult; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Health Services Accessibility; Hepacivirus; Hepatitis C; Humans; Ireland; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; Program Evaluation; Prospective Studies; Registries; Ribavirin; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Uridine Monophosphate | 2017 |
Synthesis of diastereomerically pure nucleotide phosphoramidates.
Topics: Amides; Amino Acids; Antiviral Agents; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; DNA-Directed RNA Polymerases; Electrons; Esters; Hepacivirus; Hepatitis C; Humans; Magnetic Resonance Spectroscopy; Nucleosides; Nucleotides; Phenols; Phosphoric Acids; Prodrugs; Sofosbuvir; Stereoisomerism; Structure-Activity Relationship; Uridine Monophosphate; Viral Proteins | 2011 |
Synthesis of stable isotope labeled analogs of the anti-hepatitis C virus nucleotide prodrugs PSI-7977 and PSI-352938.
Topics: Antiviral Agents; Cyclic P-Oxides; Halogenation; Hepacivirus; Hepatitis C; Humans; Isotope Labeling; Nucleosides; Prodrugs; Sofosbuvir; Uridine Monophosphate | 2011 |
Trial watch: an all-oral and interferon-free future for HCV therapy?
Topics: Administration, Oral; Clinical Trials, Phase III as Topic; Forecasting; Hepatitis C; Humans; Interferons; Nucleic Acid Synthesis Inhibitors; RNA-Dependent RNA Polymerase; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins | 2011 |
Molecular modeling comparison of the performance of NS5b polymerase inhibitor (PSI-7977) on prevalent HCV genotypes.
Topics: Amino Acid Sequence; Antiviral Agents; Catalytic Domain; Enzyme Inhibitors; Genotype; Hepacivirus; Hepatitis C; Humans; Models, Molecular; Molecular Sequence Data; Sequence Alignment; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins | 2013 |